Earlier in the series, we were honoured to be joined by Dr Tim Guilliams, the CEO and Co-Founder of Healx. Healx have created a suite of AI products and platforms to revolutionise the drug discovery process of rare diseases. It is a truly exciting time for Healx as their first process has reached clinical trials!

Tim is a tech entrepreneur from the Cambridge Cluster, passionate about using AI to accelerate treatments for rare diseases. The mission-driven technology company, Healx are pioneering the next wave of drug discovery in order to bring novel, effective treatments to rare disease patients around the world.

In this role, Tim has been listed in ⁠The Sunday Times Maserati 100 ⁠list of entrepreneurs in 2019, was named as ‘One to watch’ in The Telegraph’s ⁠Top 50 Most Ambitious Business Leaders⁠ in 2020, and was selected as a member of the Forbes Technology Council in 2022.

Tim is also the Co-Founder and Trustee of the Cambridge Rare Disease Network (CRDN). Prior to Healx and CRDN, he obtained his PhD at the University of Cambridge in the field of Biophysics and Neuroscience, developing nanobody technology for Parkinson's disease. Before moving to Cambridge, UK, Tim obtained an MEng in Bio- and Chemical-Engineering from the University of Brussels.